Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991-2000)
- 24 April 2003
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 102 (4) , 1541-1547
- https://doi.org/10.1182/blood-2003-02-0430
Abstract
The reported outcome of hematopoietic stem cell transplantation (HSCT) from HLA-mismatched family members has been inconsistent. The object of this study was to evaluate the true impact of HLA-mismatch by using recent data from a homogenous population, excluding HSCT procedures that used graft manipulations, and by considering genotypic matching. Clinical data of 2947 patients who underwent allogeneic HSCT for leukemia or myelodysplastic syndrome were extracted from the database of the Japan Society for Hematopoietic Cell Transplantation. The main outcome measures were survival and the incidence of graft-versus-host disease (GVHD). The presence of serologic HLA-mismatch, higher age, and high-risk disease were identified as independent risk factors for both shorter survival and the development of grade III to IV acute GVHD. The impact of HLA-mismatch on survival was more relevant in standard-risk patients. These findings persisted when we used genotypic HLA matching. Survival after one-locus–mismatched HSCT was equivalent to that after HLA-matched unrelated HSCT. We concluded that when a one-locus–mismatched family donor is available for high-risk patients, immediate HSCT using this donor is warranted. In standard-risk patients, however, survival after one-locus–mismatched HSCT is significantly shorter than that after HLA-matched HSCT, and the indications for HSCT should be considered carefully.Keywords
This publication has 11 references indexed in Scilit:
- Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemiaBlood, 2002
- Transplantation of Bone Marrow as Compared with Peripheral-Blood Cells from HLA-Identical Relatives in Patients with Hematologic CancersNew England Journal of Medicine, 2001
- Hospital capacity and post-transplant survival after allogeneic bone marrow transplantation: analysis of data from the Japan Society for Hematopoietic Cell TransplantationBone Marrow Transplantation, 2000
- Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trialThe Lancet, 2000
- A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignanciesBone Marrow Transplantation, 1998
- Effect of Matching of Class I HLA Alleles on Clinical Outcome after Transplantation of Hematopoietic Stem Cells from an Unrelated DonorNew England Journal of Medicine, 1998
- Haploidentical family member transplants for patients with chronic myeloid leukaemia: a report of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)Bone Marrow Transplantation, 1997
- Treatment of leukemia with partially matched related bone marrow transplantationBone Marrow Transplantation, 1997
- BONE MARROW TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA FROM GENOTYPICALLY HLA-NONIDENTICAL RELATIVESTransplantation, 1996
- Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphomaHuman Immunology, 1990